Aperbio Technologies (Suzhou) Co., Ltd.

Exploring Life, Illuminating Health with Technology Innovation

At the forefront of life sciences, Aperbio emerged with a deep commitment to human health. Our story began with our founders' mission to "Precision for Life" combining life sciences with instrument sciences, conducting innovative instrument manufacturing and diagnostic reagent research and development, promoting the coordinated development of biological life science research and clinical diagnosis, and aiming to provide accurate and rapid solutions for human health.

Pangaea Opening New Frontiers: Our "Pangaea" rapid real-time PCR instrument processes up to 96 samples in a single run, with the fastest detection time of just 30 minutes. With its groundbreaking patented technology, it has been approved by the CFDA and CE certification, and has become a new tool in scientific research and clinical diagnostics. This not only showcases Aperbio's technical prowess in molecular diagnostics but also embodies our spirit of innovation.

Aperbio's in-depth strategic cooperation with international biotech companies such as Stilla in France and ECHO in the USA facilitate continuous innovation of its products and technologies. Additionally, we have established close partnerships with various international academic institutions, distributors, and medical organizations, actively expanding our global market presence and promoting collaboration and innovation in the field of in vitro diagnostics.

Aperbio's R&D team consists of several experienced returnee PhDs with a solid foundation in molecular biology research. The company has established internationally advanced R&D platforms for digital PCR, rapid fluorescent quantitative PCR, and fluorescent microscopy imaging and analysis. We have obtained multiple national patents related to nucleic acid micro-detection and digital PCR. Our products have passed ISO 13485 and ISO 9001 quality system certifications, indicating that their quality and services have received international recognition.

Aperbio's Naica CN digital PCR system, Pangaea real-time PCR system, and various reagent products have received medical device registration approvals, production licenses, and CE certification, officially entering the clinical application market. This marks their competitiveness and influence in the international market.

Looking ahead, Aperbio will continue to delve into the fields of Instrumental science, life science research and translational applications, committed to providing innovative solutions for global customers. We believe that through relentless effort, Aperbio will contribute even more to the future of human health.